Elicio Therapeutics, Inc. (NASDAQ:ELTX) Financings

Elicio Therapeutics, Inc.

Financings

RaiseDate
Registered direct offering of shares of common stock
Closed: US$15M in the latest tranche · Titan Partners, a division of American Capital Partners +1
Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.
Use of proceeds: Support the planned Phase 1 development of ELI-002 7P in metastatic pancreatic cancer and advance the pipeline
Aug 13, 2026
Registered direct offering of common stock
Announced: about US$15M · Titan Partners, a division of American Capital Partners +1
Dealers: Titan Partners, a division of American Capital Partners (lead), B. Riley Securities, Inc.
Use of proceeds: Fund planned Phase 1 development of ELI-002 7P in metastatic PDAC, the pipeline and platform, working capital and general corporate purposes
Jul 2, 2026
At-the-market programme of shares under at-the-market program
Tranche closed: US$11.1M raised
Nov 13, 2025
Senior secured promissory note with warrants
Closed: US$10M raised · Warrants at US$7.75 for 60 months
Buyers: GKCC, LLC (existing investor; $10 million senior secured promissory note and warrants to purchase 103,225 shares)
Use of proceeds: With existing cash, to support operations into Q1 2026, beyond the AMPLIFY-7P Phase 2 interim analysis expected in Q3 2025
Jun 4, 2025

Read by 6ix AI from the company's releases